Genkyotex: Disclosure of the Total Number of Voting Rights & Shares Pursuant to Article L. 233-8 II of the French Commercial ...
September 14 2018 - 11:45AM
Business Wire
(AMF – Autorité des Marchés
Financiers)
Regulatory News:
Genkyotex (Paris:GKTX) (Brussels:GKTX):
Genkyotex shares
ISIN code FR00011790542 – Euronext
Paris & Brussels
Date
Number of shares making up
the share capital
Number of voting rights
August 31,2017
77,917,255 Theoretical number of voting rights(1):
77,917,255 Number of voting rights exercisable at a
shareholders’meeting(2): 77,851,344
(1) In accordance with Article 223-111 of the AMF’s General
Regulation, this number of shares is calculated based on all shares
carrying the right to vote, including those stripped of voting
rights.(2) Less shares stripped of voting rights.
About Genkyotex
Genkyotex is the leading biopharmaceutical company in NOX
therapies, listed on the Euronext Paris and Euronext Brussels
markets. A leader in NOX therapies, its unique therapeutic approach
is based on a selective inhibition of NOX enzymes that amplify
multiple disease processes such as fibrosis, inflammation, pain
processing, cancer development, and neurodegeneration.
Genkyotex’s platform enables the identification of available
small-molecules that selectively inhibit specific NOX enzymes.
Genkyotex is developing a pipeline of first-in-class product
candidates targeting one or multiple NOX enzymes. The lead product
candidate, GKT831, a NOX1 and NOX4 inhibitor is evaluated in a
phase II clinical trial in primary biliary cholangitis (PBC, a
fibrotic orphan disease) and in an investigator-initiated Phase II
clinical trial in Type 1 Diabetes and Kidney Disease (DKD). A grant
from the United States National Institutes of Health (U.S. NIH) of
$8.9 million has been awarded to Professor Victor Thannickal at the
University of Alabama at Birmingham (UAB) to fund a multi-year
research program evaluating the role of NOX enzymes in idiopathic
pulmonary fibrosis (IPF), a chronic lung disease that results in
fibrosis of the lungs, the core component of the program will be to
conduct a Phase 2 trial with the GKT831 in patients with IPF. This
product candidate may also be active in other fibrotic indications.
Its second product candidate, GKT771, is a NOX1 inhibitor targeting
multiple pathways in angiogenesis, pain processing, and
inflammation, currently undergoing preclinical testing.
Genkyotex also has a versatile platform well-suited to the
development of various immunotherapies (Vaxiclase). A partnership
has been established with Serum Institute of India Private Ltd
(Serum Institute) and could generate approximately €150 million in
future revenues for Genkyotex, before royalties on sales.
For further information, please go to
www.genkyotex.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180914005199/en/
Genkyotex